BACKGROUND: Sex steroid hormone receptors mediate essential processes in normal prostate growth and contribute to prostate cancer development. METHOD: In this study, we investigated the association between common inherited variation of the AR, ESR1, and ESR2 genes and two clinically relevant traits: the risk of developing aggressive prostate cancer and the response to androgen deprivation therapy (ADT) in a hospital-based cohort. A total of 43 tagging single nucleotide polymorphisms covering the loci of AR (n = 4), ESR1 (n = 32), and ESR2 (n = 7) were successfully genotyped in 4,073 prostate cancer cases. RESULTS: None of these single nucleotide polymorphisms were significantly associated with disease aggressiveness as assessed by the D'Amico risk classification, pathologic stage, or the response to ADT. CONCLUSIONS: Our results suggest that common genetic variations in AR, ESR1, or ESR2 are not strongly associated with prostate cancer aggressiveness or response to ADT. IMPACT: Our study did not find convincing evidence of inherited variations in the major receptors for androgens and estrogens and their associations with prostate cancer traits.
BACKGROUND: Sex steroid hormone receptors mediate essential processes in normal prostate growth and contribute to prostate cancer development. METHOD: In this study, we investigated the association between common inherited variation of the AR, ESR1, and ESR2 genes and two clinically relevant traits: the risk of developing aggressive prostate cancer and the response to androgen deprivation therapy (ADT) in a hospital-based cohort. A total of 43 tagging single nucleotide polymorphisms covering the loci of AR (n = 4), ESR1 (n = 32), and ESR2 (n = 7) were successfully genotyped in 4,073 prostate cancer cases. RESULTS: None of these single nucleotide polymorphisms were significantly associated with disease aggressiveness as assessed by the D'Amico risk classification, pathologic stage, or the response to ADT. CONCLUSIONS: Our results suggest that common genetic variations in AR, ESR1, or ESR2 are not strongly associated with prostate cancer aggressiveness or response to ADT. IMPACT: Our study did not find convincing evidence of inherited variations in the major receptors for androgens and estrogens and their associations with prostate cancer traits.
Authors: Paul I W de Bakker; Roman Yelensky; Itsik Pe'er; Stacey B Gabriel; Mark J Daly; David Altshuler Journal: Nat Genet Date: 2005-10-23 Impact factor: 38.330
Authors: William K Oh; Julia Hayes; Carolyn Evan; Judith Manola; Daniel J George; Helen Waldron; Meaghan Donovan; John Varner; John Orechia; Beth Katcher; Diana Lu; Arthur Nevins; Renée L Wright; Lauren Tormey; James Talcott; Mark A Rubin; Massimo Loda; William R Sellers; Jerome P Richie; Philip W Kantoff; Jane Weeks Journal: Clin Genitourin Cancer Date: 2006-06 Impact factor: 2.872
Authors: Matthew L Freedman; Celeste L Pearce; Kathryn L Penney; Joel N Hirschhorn; Laurence N Kolonel; Brian E Henderson; David Altshuler Journal: Am J Hum Genet Date: 2004-11-29 Impact factor: 11.025
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: Camilla Thellenberg-Karlsson; Sara Lindström; Beatrice Malmer; Fredrik Wiklund; Katarina Augustsson-Bälter; Hans-Olov Adami; Par Stattin; Maria Nilsson; Karin Dahlman-Wright; Jan-Ake Gustafsson; Henrik Grönberg Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: Manish Kohli; Shaun M Riska; Douglas W Mahoney; High S Chai; David W Hillman; David N Rider; Brian A Costello; Rui Qin; Jatinder Lamba; Deepak M Sahasrabudhe; James R Cerhan Journal: Mayo Clin Proc Date: 2012-03 Impact factor: 7.616
Authors: Tong Sun; Lee Gwo-Shu Mary; William K Oh; Matthew L Freedman; Mark Pomerantz; Kenneth J Pienta; Philip W Kantoff Journal: Clin Cancer Res Date: 2010-12-06 Impact factor: 12.531
Authors: Tong Sun; William K Oh; Susanna Jacobus; Meredith Regan; Mark Pomerantz; Matthew L Freedman; Gwo-Shu Mary Lee; Philip W Kantoff Journal: Cancer Prev Res (Phila) Date: 2011-09-07
Authors: Jana Jurečeková; Monika Kmeťová Sivoňová; Henrieta Drobková; Márk Híveš; Daniel Evin; Ján Kliment; Dušan Dobrota Journal: Oncol Lett Date: 2021-01-19 Impact factor: 2.967